AU2022387516A1 - Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions - Google Patents
Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions Download PDFInfo
- Publication number
- AU2022387516A1 AU2022387516A1 AU2022387516A AU2022387516A AU2022387516A1 AU 2022387516 A1 AU2022387516 A1 AU 2022387516A1 AU 2022387516 A AU2022387516 A AU 2022387516A AU 2022387516 A AU2022387516 A AU 2022387516A AU 2022387516 A1 AU2022387516 A1 AU 2022387516A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- imidazo
- benzyl
- pyrazol
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21207942.0 | 2021-11-12 | ||
| EP21207942.0A EP4180428A1 (en) | 2021-11-12 | 2021-11-12 | Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions |
| PCT/US2022/049695 WO2023086564A1 (en) | 2021-11-12 | 2022-11-11 | Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022387516A1 true AU2022387516A1 (en) | 2024-05-23 |
Family
ID=78617277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022387516A Pending AU2022387516A1 (en) | 2021-11-12 | 2022-11-11 | Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11814383B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP4180428A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024543413A (cg-RX-API-DMAC10.html) |
| CN (1) | CN118843624A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022387516A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3237156A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL312625A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024005766A (cg-RX-API-DMAC10.html) |
| TW (1) | TW202334143A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023086564A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9067914B1 (en) * | 2013-12-10 | 2015-06-30 | Genzyme Corporation | Tropomyosin-related kinase (TRK) inhibitors |
| EP4180428A1 (en) | 2021-11-12 | 2023-05-17 | Genzyme Corporation | Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions |
| AU2024273547A1 (en) * | 2023-05-17 | 2025-12-04 | Centrexion Therapeutics Corporation | PARTICLES OF IMIDAZO [4,5-b] PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL150524A0 (en) * | 2000-01-07 | 2003-02-12 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| US9067914B1 (en) | 2013-12-10 | 2015-06-30 | Genzyme Corporation | Tropomyosin-related kinase (TRK) inhibitors |
| MA40698A3 (fr) | 2014-12-18 | 2020-01-31 | Genzyme Corp | Formulations pharmaceutiques d'inhibiteurs de kinase associée à la tropomyosine (trk) |
| CA3080157A1 (en) | 2017-10-26 | 2019-05-02 | Array Biopharma Inc. | Formulations of a macrocyclic trk kinase inhibitor |
| EP3773725A1 (en) | 2018-03-29 | 2021-02-17 | Loxo Oncology Inc. | Treatment of trk-associated cancers |
| MX2021001957A (es) | 2018-08-22 | 2021-07-15 | Cullgen Shanghai Inc | Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk). |
| BR112022016901A2 (pt) * | 2020-02-26 | 2022-12-06 | Cullgen Shanghai Inc | Compostos de degradação do receptor de tropomiosina quinase (trk) e métodos de uso |
| EP4180428A1 (en) | 2021-11-12 | 2023-05-17 | Genzyme Corporation | Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions |
-
2021
- 2021-11-12 EP EP21207942.0A patent/EP4180428A1/en not_active Withdrawn
-
2022
- 2022-11-11 MX MX2024005766A patent/MX2024005766A/es unknown
- 2022-11-11 JP JP2024527604A patent/JP2024543413A/ja active Pending
- 2022-11-11 US US17/985,531 patent/US11814383B2/en active Active
- 2022-11-11 EP EP22893662.1A patent/EP4430043A4/en active Pending
- 2022-11-11 WO PCT/US2022/049695 patent/WO2023086564A1/en not_active Ceased
- 2022-11-11 TW TW111143263A patent/TW202334143A/zh unknown
- 2022-11-11 CA CA3237156A patent/CA3237156A1/en active Pending
- 2022-11-11 AU AU2022387516A patent/AU2022387516A1/en active Pending
- 2022-11-11 CN CN202280087913.4A patent/CN118843624A/zh active Pending
- 2022-11-11 IL IL312625A patent/IL312625A/en unknown
-
2023
- 2023-11-09 US US18/505,713 patent/US12291528B2/en active Active
-
2025
- 2025-04-22 US US19/185,943 patent/US20250250274A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202334143A (zh) | 2023-09-01 |
| US11814383B2 (en) | 2023-11-14 |
| US20240150352A1 (en) | 2024-05-09 |
| US12291528B2 (en) | 2025-05-06 |
| EP4180428A1 (en) | 2023-05-17 |
| JP2024543413A (ja) | 2024-11-21 |
| US20230151008A1 (en) | 2023-05-18 |
| MX2024005766A (es) | 2024-07-29 |
| US20250250274A1 (en) | 2025-08-07 |
| IL312625A (en) | 2024-07-01 |
| EP4430043A1 (en) | 2024-09-18 |
| EP4430043A4 (en) | 2025-11-05 |
| WO2023086564A1 (en) | 2023-05-19 |
| CA3237156A1 (en) | 2023-05-19 |
| CN118843624A (zh) | 2024-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12291528B2 (en) | Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions | |
| JP7198820B2 (ja) | 置換アゼチジンジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用 | |
| TW200806664A (en) | Azaindoles useful as inhibitors of janus kinases | |
| AU2017201916B2 (en) | Salts, co-crystals, and polymorphs of an anxiolytic compound | |
| WO2020042995A1 (zh) | 一种高活性sting蛋白激动剂化合物 | |
| JP2020526557A (ja) | ムスカリン性アセチルコリン受容体m4のアンタゴニスト | |
| JP6302480B2 (ja) | 中枢神経系疾患の治療に有用なトリアゾロ−ピラジン誘導体 | |
| US12171758B1 (en) | Crystalline salt forms of kappa opioid receptor antagonist and products and methods related thereto | |
| CA2769149A1 (en) | Compositions and methods for treating parkinson's disease | |
| JP2002504134A (ja) | 疼痛を治療するためのドラフラジン類似体の使用 | |
| KR100882925B1 (ko) | 세로토닌 5-ht₃a 길항적 효과를 갖는 피라졸 유도체함유 약제 조성물 | |
| US20240383892A1 (en) | PARTICLES OF IMIDAZO[4,5-b]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS | |
| WO2009050554A2 (en) | Treatment of central nervous system disorders | |
| CN100491378C (zh) | 新的取代四环咪唑衍生物,其制备方法,包含它们的药物组合物及它们作为药物的用途 | |
| KR20240115109A (ko) | 고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학 조성물 | |
| CN121949280A (zh) | 一种多取代吲哚类化合物及其制备方法和用途 | |
| KR20230068877A (ko) | 고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학적 조성물 | |
| HK40009154A (en) | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use | |
| HK40009151A (en) | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use | |
| EA045384B1 (ru) | Твердые формы ингибитора glyt1 | |
| WO2003087091A1 (en) | Novel crystal of quinoxalinedione derivative anhydride | |
| JPH11512403A (ja) | 2,3,4,5−テトラヒドロ−1h−3−ベンズアゼピン化合物の酸付加塩 |